Mark Parker

RxLogix Corporation

RxLogix is a one-stop-shop for all PV needs applying the most recent technology advances like machine learning, artificial intelligence, and best practice methodological approaches. After a thorough evaluation of commercially available signaling and analytical software vendors, the FDA selected RxLogix's PV Surveillance Suite Platform, replacing their legacy FAERS signaling system. FDA has decided to implement RxLogix PV Surveillance Suite (Modules – PV Reports, PV Signal, PV Analytics, and PV Datahub) for advanced data analytics, signal detection, evaluation, signal management, and benefit-risk assessment. RxLogix experienced team of business and technology innovators work with Pharmacovigilance and Risk Management Professionals to help increase the compliance, productivity, and quality for the entire Drug Safety value chain thus ensuring patient safety. RxLogix highly values defiant bold thinkers entrenched in the world of science, medicine, and innovation. From a strategic perspective, RxLogix proactively seeks innovative solutions as preemptive strikes against second-rate thinking.